By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Mental Health. According to news reporting originating from Halifax, Canada, by NewsRx correspondents, research stated, "Antidepressant response varies between patients, possibly due to differences in the rate cytochrome P450 enzymes metabolise antidepressants into inactive compounds. Drug metabolism rates are influenced by common variants in the genes encoding these enzymes."
Our news editors obtained a quote from the research from Dalhousie University, "However, it remains unclear whether treatment outcomes can be predicted by either CYP450 genotype or antidepressant serum concentration. In GENDEP (a pharmacogenetic study of depressed individuals treated with either escitalopram or nortriptyline), serum concentrations of antidepressants and their primary metabolite were measured after eight weeks treatment and variants in CYP2D6 and CYP2C19 were genotyped. Amongst patients taking escitalopram (n=223), the genotype CYP2C19 was significantly associated with escitalopram serum concentrations and desmethylescitalopram:escitalopram ratio. For those taking nortriptyline (n=161), the CYP2D6 genotype was significantly associated with nortriptyline and 10-hydroxynortriptyline serum concentrations and 10-hydroxynortriptyline:nortrip-tyline ratio. CYP450 genotypes conferring greater enzyme activity were linked to lower drug serum concentrations and higher metabolite:drug ratios. Nonetheless, no significant association was found between either CYP450 genotype or antidepressant serum concentration and treatment response. While there is a significant relationship between the CYP450 genotype and serum concentrations of escitalopram and nortriptyline, the genotypes are not predictive of differences in treatment response for either drug."
According to the news editors, the research concluded: "Furthermore, differences in antidepressant serum concentrations are not associated with variability in treatment response."
For more information on this research see: Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. Journal of Psychopharmacology, 2014;28(2):133-141. Journal of Psychopharmacology can be contacted at: Sage Publications Ltd, 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England. (Sage Publications - www.sagepub.com/; Journal of Psychopharmacology - jop.sagepub.com)
The news editors report that additional information may be obtained by contacting K. Hodgson, Dalhousie University, Dept. of Psychiat, Halifax, NS, Canada. Additional authors for this research include K. Tansey, M.Z. Dernovsek, J. Hauser, N. Henigsberg, W. Maier, O. Mors, A. Placentino, M. Rietschel, D. Souery, R. Smith, I.W. Craig, A.E. Farmer, K.J. Aitchison, S. Belsy, O.S.P. Davis, R. Uher and P. McGuffin (see also Mental Health).
Keywords for this news article include: Drugs, Canada, Halifax, Genetics, Treatment, Nova Scotia, Cytochromes, Escitalopram, Hemeproteins, Mental Health, Nortriptyline, Dibenzocycloheptenes, Enzymes and Coenzymes, Psychotherapeutic Agents, North and Central America, Tricyclic Antidepressants, Serotonin Uptake Inhibitors, Norepinephrine Reuptake Inhibitors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC